BioStock: Status Report Cereno Scientific – an undervalued Phase II company

BioStock has performed a Status Report of Cereno Scientific, a company that develops CS1. The Phase II candidate has the potential to redefine the field of thrombosis prevention.

Read more



3rd annual Anti-Fibrotic Drug Development Summit (AFDD) 2019-11-18 - 2019-11-20

16th Global Cardiovascular Clinical Trialists Forum 2019-12-05 - 2019-12-07

LeadingBiotech: East/West CEO 2020-01-11 - 2020-01-12

Biotech Showcase™ 2020 2020-01-13 - 2020-01-15

More about us...

Subscribe for corporate news

Follow us on LinkedIn

Follow us on Twitter

Privacy policy

We are proud supporters of World Thrombosis Day. Read more